Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 278.00, up by 5.80 points or 2.13% from its previous closing of Rs. 272.20 on the BSE.
The scrip opened at Rs. 280.00 and has touched a high and low of Rs. 293.90 and Rs. 276.60 respectively. So far 34639 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 532.40 on 12-Jan-2018 and a 52 week low of Rs. 268.00 on 15-Nov-2018.
Last one week high and low of the scrip stood at Rs. 293.90 and Rs. 271.00 respectively. The current market cap of the company is Rs. 7117.72 crore.
The promoters holding in the company stood at 68.11%, while Institutions and Non-Institutions held 8.62% and 23.27% respectively.
Sun Pharma Advanced Research Company (SPARC) has reported top-line results of the pivotal BE study for Paclitaxel Injection Concentrate for Suspension (PICS).
The pivotal BE study was a randomized, open label, two period, single dose, crossover study of PICS and Abraxane in subjects with locally recurrent or metastatic breast cancer.
A total of 142 patients were randomized to characterize the pharmacokinetic (PK) profile of PICS for both unbound and total paclitaxel compared with Abraxane. The study also provided information on the safety profile of PICS. The study met all the required pharmacokinetic endpoints for both unbound and total paclitaxel. There were no new adverse events observed in this study.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: